What the FDA Found
The FDA reviewed 305 case reports of dental adverse events associated with buprenorphine medicines dissolved in the mouth, submitted to the FDA Adverse Event Reporting System (FAERS) between the time these medicines were approved and October 2021. The FDA found that the dental problems reported were severe. The most common adverse events reported were tooth decay, cavities, oral infections, and tooth fractures. Some of the reported cases resulted in tooth loss. In 26 cases, patients required complete tooth removal. Treatment reported to address these issues included root canals, tooth extractions, dental implants, and dentures.
The FDA noted that the dental problems occurred in patients with no prior history of dental disease, as well as in patients who reported good dental hygiene. The agency found that the dental adverse events occurred with all dosages, formulations, and durations of buprenorphine sublingual treatment. These findings confirmed that the dental injury risk is a product characteristic — not a result of patient behavior — strengthening the legal argument that Indivior's failure to warn was causally connected to the injuries sustained.
What the FDA Required Manufacturers to Do
As a result of its safety review, the FDA required manufacturers of buprenorphine medicines dissolved in the mouth to add new warnings to their prescribing information and patient medication guides. The new labeling warns about the risk of serious dental problems and advises patients to: rinse their mouth gently with water after the medicine has fully dissolved, gently rub the water around their teeth and gums, and wait at least one hour before brushing teeth. The FDA also advised patients to tell their dentist that they are using buprenorphine and to seek routine dental care during treatment. The fact that these simple, effective mitigation steps exist — and were never communicated to patients before January 2022 — underscores the preventable nature of the dental injuries and the significance of Indivior's failure to warn.
Legal Significance: The Discovery Rule and the January 12, 2022 Date
In product liability law, the statute of limitations clock starts when the plaintiff knew or should have known that a product caused their injury — not necessarily when the injury occurred. Before January 12, 2022, most patients who had sustained dental injuries while taking Suboxone had no official basis to connect their medication to their tooth damage. The FDA's safety communication provides a documentable, objective date on which the Suboxone-dental injury connection was established by the federal government. Plaintiff attorneys across the country are arguing that this date resets or triggers the statute of limitations for affected patients — meaning that patients in 2-year SOL states had until January 12, 2024, and patients in 3-year SOL states had until January 12, 2025, to file claims. Courts have not uniformly adopted this interpretation, and individual circumstances (such as a dentist noting a possible Suboxone connection before 2022) can affect the analysis. Consultation with an attorney is essential.
Frequently Asked Questions
Related Pages
Suboxone Dental Damage Explained
Suboxone sublingual film strips damage teeth through a chemical acid erosion mechanism. Citric acid in the film creates a highly acidic oral environment during dissolution, dissolving tooth enamel with repeated daily exposure. This process is distinct from ordinary tooth decay and produces a characteristic pattern of rapid, widespread, smooth-surface erosion that dentists can document in dental records.
Suboxone Statute of Limitations by State
Suboxone dental injury claims are subject to state product liability statutes of limitations, typically 2 to 3 years, which may run from the January 12, 2022 FDA safety communication under the discovery rule. Deadlines vary significantly by state and individual circumstances — time is critical and consultation with an attorney is the only reliable way to determine your specific deadline.
Suboxone Dental Records and Evidence Gathering
Dental records — including clinical notes, X-rays, and billing documentation — are the evidentiary foundation of every Suboxone dental injury claim. Gathering them promptly is critical because dental practices have limited record retention requirements and older records may be unavailable from closed or sold practices.
Suboxone Settlement Amounts and Expectations
Reported Suboxone dental injury settlements have ranged from approximately $35,000 for minor-to-moderate cases to $250,000 or more for complete tooth loss requiring full-mouth reconstruction. The MDL is ongoing and no global settlement has been announced — individual case values depend heavily on injury severity, documentation quality, and state-specific legal factors.
Indivior's Failure to Warn
Indivior, the manufacturer of Suboxone, had access to medical literature and adverse event data establishing the dental risk of its sublingual film formulation for years before adding dental warnings to its label. Under pharmaceutical product liability law, this gap between knowledge and disclosure forms the foundation of the failure-to-warn claims at the center of Suboxone dental injury litigation.
Suboxone Dental Injury Qualification Criteria
Not every Suboxone user who experienced dental problems has a viable legal claim. Qualifying cases generally involve significant dental injuries — multiple cavities, extractions, tooth loss, or reconstruction — developed during Suboxone use, documented in dental records, and timely filed. Understanding the criteria helps patients determine whether to pursue a claim.
Suboxone vs. Generic Buprenorphine Film
The dental injury risk from buprenorphine sublingual film is not unique to the Suboxone brand — generic buprenorphine/naloxone sublingual films share the same acidic excipient mechanism and the same dental injury profile. However, pursuing claims against generic manufacturers involves different legal considerations than brand-name product liability claims under both federal and state law.
Suboxone Dental Treatment Costs
Dental rehabilitation costs for Suboxone-related injuries can range from several thousand dollars for restorations to $80,000 or more for full-mouth implant-supported reconstruction. These documented costs form the economic damages component of a claim and are recoverable in litigation. Understanding the cost breakdown helps patients evaluate the potential value of their claim.
How to File a Suboxone Dental Injury Lawsuit
Filing a Suboxone dental injury lawsuit begins with gathering dental and prescription records, consulting a pharmaceutical litigation attorney, and submitting a complaint. Most cases are filed in or transferred to MDL 3092 in the Northern District of Ohio. The process is handled almost entirely by the attorney, with no upfront costs under a contingency fee arrangement.
Suboxone Class Action vs. Individual Claims
Suboxone dental injury litigation is structured as a multidistrict litigation (MDL), not a class action. In an MDL, plaintiffs retain individual claims and individual damages — each client's recovery is based on their specific injuries, not shared with others. Understanding this distinction helps plaintiffs know what to expect from the process.
MAT Patients and Dental Stigma
People in recovery from opioid use disorder who experienced Suboxone-related tooth loss face a unique double stigma: societal bias against addiction, and the unfair association between visible tooth loss and substance use. These psychological and social harms are legally compensable non-economic damages, and addressing them with compassion and dignity is central to how these cases should be litigated.
Suboxone Tooth Decay Lawsuit
Suboxone sublingual film strips — a medication-assisted treatment (MAT) for opioid use disorder — dissolve under the tongue and contain citric acid and other acidic excipients that, with repeated use, erode tooth enamel and cause rapid, severe dental decay. Thousands of patients who faithfully took Suboxone as prescribed to manage opioid dependence later discovered they had lost multiple teeth, required extensive dental reconstruction, or faced thousands of dollars in oral surgery costs — through no fault of their own. Manufacturer Indivior (formerly part of Reckitt Benckiser) knew or should have known about these dental risks for years but failed to include adequate warnings on the product label. The FDA confirmed the danger with a formal safety communication on January 12, 2022, requiring updated product labeling. Patients who suffered dental injuries while using Suboxone sublingual film may have valid product liability claims against Indivior for failure to warn.
View full case overview